Information Provided By:
Fly News Breaks for December 18, 2019
Dec 18, 2019 | 06:33 EDT
JMP Securities analyst Reni Benjamin initiated coverage of Iovance Biotherapeutics with an Outperform rating and $38 price target. The analyst cites the company's multiple ongoing pivotal trials in melanoma and cervical cancer, noting that the clinical data from its earlier trials demonstrated "impressive efficacy." Benjamin adds that Iovance is also conducting tumor infiltrating lymphocytes, or TIL, trials in head/ neck cancer and non-small cell lung cancer as well as other indications.
News For IOVA From the Last 2 Days
There are no results for your query IOVA